What is Zacks Research’s Estimate for TEVA FY2026 Earnings?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Analysts at Zacks Research decreased their FY2026 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a research report issued on Tuesday, December 3rd. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.75 per share for the year, down from their previous estimate of $2.77. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.36 per share.

Several other analysts have also issued reports on TEVA. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group lifted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $17.83 on Thursday. Teva Pharmaceutical Industries has a 52-week low of $9.35 and a 52-week high of $19.31. The stock has a market cap of $20.20 billion, a PE ratio of -20.98, a price-to-earnings-growth ratio of 1.35 and a beta of 0.79. The business has a 50-day simple moving average of $17.54 and a 200-day simple moving average of $17.37. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its position in shares of Teva Pharmaceutical Industries by 141.7% during the third quarter. Franklin Resources Inc. now owns 155,091 shares of the company’s stock worth $2,674,000 after purchasing an additional 90,920 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $50,000. Sanctuary Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after buying an additional 664 shares during the last quarter. TCW Group Inc. acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth about $1,286,000. Finally, Geode Capital Management LLC lifted its holdings in Teva Pharmaceutical Industries by 3.4% in the third quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock worth $157,571,000 after acquiring an additional 291,124 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.55% of the stock is currently owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.